Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Form 144 Notice of Proposed Sale filed by Natera insider indicates planned sale of 19,908 shares of common stock with an aggregate market value of $3,335,585.40. The sale is scheduled for June 18, 2025, to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.
The securities were originally acquired as Restricted Stock Units from the issuer on September 21, 2020. The seller, Daniel Rabinowitz, has conducted three previous sales in the past 3 months totaling 3,867 shares with gross proceeds of $566,033.98:
- April 28, 2025: 1,993 shares for $303,299.52
- April 21, 2025: 470 shares for $68,407.52
- March 31, 2025: 1,404 shares for $194,326.94
The company currently has 136,546,580 shares outstanding. This proposed sale represents approximately 0.015% of total shares outstanding.